Charak Pharma Private Limited

Charak Pharma Private Limited, established on June 8, 2000, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2000PTC127072. As of the latest available data, Charak Pharma has an authorized capital of ₹71 million and a paid-up capital of ₹68.76 million. The company is classified as a non-government entity limited by shares.

Charak Pharma specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with a focus on Ayurvedic and herbal products. The company has a significant presence in the Indian market, with many of its brands being category leaders. Internationally, Charak Pharma exports its products to various countries across continents, including Russia, Ukraine, Kazakhstan, Kenya, South Africa, Sri Lanka, Malaysia, Greece, Bulgaria, Portugal, the Netherlands, and the USA. The company's commitment to quality is affirmed through stringent quality checks and clinical studies, and its manufacturing facilities have been awarded the WHO-GMP certification.

Charak Pharma operates manufacturing facilities in Mumbai, Maharashtra, India. The company's manufacturing plant is located at Evergreen Industrial Estate, Dr. E Moses Road, Shakti Mills Lane, Mahalaxmi, Mumbai, Maharashtra 400011. The facilities are equipped to produce a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, with a specialization in Ayurvedic and herbal products. The manufacturing processes adhere to stringent quality standards, and the facilities have been awarded the WHO-GMP certification, ensuring compliance with international quality norms.

Charak Pharma's leadership team comprises several key individuals:

• Nimish Shroff Kishor: Director since June 8, 2000.
• Vikram Shroff Kishor: Director since June 8, 2000.
• Pulin Shroff Harshad: Managing Director since June 8, 2000.
• Ram Hemant Shroff: Director since June 8, 2000.
• Raj Hemant Shroff: Whole-Time Director since June 8, 2000.
• Murali Ganapathi Kizhakkenchery: Company Secretary since March 30, 2017.

These individuals have been instrumental in steering the company towards its current position in the pharmaceutical industry.

Charak Pharma has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's products are manufactured in compliance with international quality standards, and its facilities have been awarded the WHO-GMP certification, which is recognized by regulatory authorities in these regions. This certification ensures that Charak Pharma's manufacturing processes meet the stringent requirements set by global health authorities.

Charak Pharma has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's commitment to quality and efficacy has facilitated its entry into these regions, where there is a growing demand for herbal and Ayurvedic products. The WHO-GMP certification of Charak Pharma's manufacturing facilities enhances its credibility and acceptance in these markets, enabling the company to meet the regulatory requirements and consumer expectations in these regions.

Charak Pharma's geographic strategy involves a balanced approach between domestic leadership and international expansion. While the company holds a strong position in the Indian market, with many of its brands being category leaders, it has also made significant inroads into international markets across continents. This diversification strategy mitigates concentration risk and positions the company for sustained growth in both established and emerging markets.

As of the latest available data, there is no specific information regarding Charak Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's manufacturing facilities are WHO-GMP certified, which may facilitate market access in the United States. However, for detailed FDA approvals and registrations, further information would be required.

Charak Pharma's manufacturing facilities have been awarded the WHO-GMP certification, ensuring compliance with international quality standards. This certification is recognized by regulatory authorities in various regions, including the European Union, facilitating market access and acceptance of Charak Pharma's products in these markets.

Charak Pharma operates in compliance with the regulations set by the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facilities adhere to the standards prescribed by CDSCO, ensuring the safety, efficacy, and quality of its pharmaceutical products. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not available in the provided information.

As of the latest available data, there are no specific reports of Form 483 observations, warning letters, or import alerts issued to Charak Pharma. The company's adherence to international quality standards, as evidenced by its WHO-GMP certification, suggests a strong compliance record. However, for detailed information on any recent regulatory actions, further research would be necessary.

Charak Pharma operates in the competitive Ayurvedic and herbal pharmaceutical market, both domestically and internationally. In India, the company faces competition from other established players in the herbal and Ayurvedic segment. Internationally, Charak Pharma competes with global pharmaceutical companies offering similar products. The company's WHO-GMP certification and commitment to quality provide a competitive edge in both domestic and international markets.

Charak Pharma's key differentiators include its extensive experience in the Ayurvedic and herbal pharmaceutical sector, a diverse product portfolio with over 50 herbal supplements, and a strong commitment to quality, as evidenced by its WHO-GMP certification. The company's focus on converting traditional herbal knowledge into modern standardized products with scientifically proven efficacy and safety sets it apart in the market.

Charak Pharma's current strategic direction focuses on expanding its presence in both domestic and international markets, leveraging its expertise in Ayurvedic and herbal pharmaceuticals. The company's WHO-GMP certification and commitment to quality position it well for future growth and market penetration. Future outlook includes further diversification of its product portfolio and exploration of new markets to sustain growth and competitiveness.

Charak Pharma has a track record of consistent export performance, with a total export value of $939K USD across 67 shipments, indicating reliability in fulfilling international orders. The company's adherence to international quality standards, as evidenced by its WHO-GMP certification, further underscores its reliability as a supplier. However, specific details regarding export volume consistency and other reliability indicators are not available in the provided information.

Importers should verify the following certifications when considering Charak Pharma as a supplier:

• WHO-GMP Certification: Ensures compliance with international quality standards. Verification can be done by requesting a copy of the certificate from Charak Pharma or checking with the World Health Organization.

• ISO Certification: Affirms adherence to quality management standards. Verification can be done by requesting a copy of the certificate from Charak Pharma or checking with the International Organization for Standardization.

When conducting due diligence on Charak Pharma, consider the following steps:

• Verify Certifications: Ensure that Charak Pharma holds valid WHO-GMP and ISO certifications.

• Assess Financial Health: Review the company's financial statements for the latest fiscal year to evaluate profitability and financial stability.

• Evaluate Compliance Records: Check for any regulatory actions, such as warning letters or import alerts, issued against the company.

• Review Product Portfolio: Examine the range and quality of products offered to ensure they meet your requirements.

• Assess Supply Chain Reliability